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Abstract
Background: A subgroup of clinical trial subjects identified by baseline characteristics is a proper
subgroup while a subgroup determined by post randomization events or measures is an improper
subgroup. Both types of subgroups are often analyzed in clinical trial papers. Yet, the extensive
scrutiny of subgroup analyses has almost exclusively attended to the former. The analysis of
improper subgroups thereby not only flourishes in numerous disguised ways but also does so
without a corresponding awareness of its pitfalls. Comparisons of the grade of angina in a heart
disease trial, for example, usually include only the survivors. This paper highlights some of the
distinct ways in which outcome based subgroup analysis occurs, describes the hazards associated
with it, and proposes a simple alternative approach to counter its analytic bias.
Results: Data from six published trials show that outcome based subgroup analysis, like proper
subgroup analysis, may be performed in a post-hoc fashion, overdone, selectively reported, and
over interpreted. Six hypothetical trial scenarios illustrate the forms of hidden bias related to it.
That bias can, however, be addressed by assigning clinically appropriate scores to the usually
excluded subjects and performing an analysis that includes all the randomized subjects.
Conclusion: A greater level of awareness about the practice and pitfalls of outcome based
subgroup analysis is needed. When required, such an analysis should maintain the integrity of
randomization. This issue needs greater practical and methodologic attention than has been
accorded to it thus far.
Background
Clinical trial data are frequently analyzed to identify sub-
groups of patients for whom a treatment is especially indi-
cated. Known as subgroup analysis (SGA), it is, in theory,
a useful venture. But the manner in which it has been
done and reported in practice has generated widespread
confusion and misleading claims.
Clinical trials, in the first place, rarely plan, or have an
adequate sample size for SGA. Often done post-hoc, it is
also regularly overdone, selectively reported, not inter-
preted with due caution, and performed without a rele-
vant test for interaction. With a marked potential to yield
unreliable assessments of the existence, direction and
extent of treatment differences for a specific category of
patients, the clinical message emanating from SGA is gen-
erally poorly justified, and may also foster unneeded
research [1-13].
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Warnings and contentions on the practice, consequently,
persist in the medical journals. The exchange between
Julian [14] and Sleight [15], and between Altman [16] and
Feinstein [17], for example, typify the contrasting views
on the topic.
In their seminal paper on this issue, Yusuf et al. [13]
describe two types of subgroups. A subgroup delineated
by baseline characteristics is called a proper subgroup
while one demarcated by a post-randomization event or
measure is an improper subgroup. Besides giving an
indepth critical evaluation of the analysis of proper sub-
groups, they also issued a strong admonition against ana-
lyzing improper subgroups. To quote:
Analysis of improper subgroups, though seductive,
can be extremely misleading, because a particular
treatment effect may influence classification to the
subgroup. Thus, an apparent subgroup effect may not
be a true effect of treatment but rather the result of
inherent characteristics of patients that led to a partic-
ular response or to the development of side effects.
In the eighteen years since this warning was issued, critical
scrutiny of improper subgroup analysis has all but ceased.
The extensive methodologic and clinical debate on SGA to
date has essentially dealt with proper subgroups. At the
most, only a brief warning on analyzing improper sub-
groups is given once in a while (for instance, Cook at al.
[18]). In practice, on the other hand, it flourishes. The cur-
rent literature is replete with such analyses done under a
broad variety of guises, and their findings often impact
therapeutic conclusions. An examination of the forms,
frequency, validity and reliability of this practice is thus
warranted.
This paper examines one category of improper subgroups,
namely, those formed in relation to a specific outcome in
a trial. Our focus is on the subsequent analysis of that sub-
group with respect to another outcome. We define such an
analysis as an outcome based subgroup analysis
(OBSGA). In a cancer trial, for example, a quality of life
measure is compared among the survivors. Or, in a trial of
acute otitis media, the presence of antibiotic resistance is
compared only among those in whom bacteria are iso-
lated.
The specific aims of this paper are (i) to draw attention to
the practice of outcome based subgroup analysis; (ii) to
present a variety of pertinent examples from the literature;
(iii) to show that the known pitfalls of baseline based SGA
also apply here; (iv) to illustrate the specific analytic chal-
lenges posed by OBSGA; and (v) to propose simple alter-
native, unbiased methods of analyzing outcome based
data.
Results and discussion
First, we define two key terms. In OBSGA, the outcome
determining the subgroup membership is called the index
outcome, and an outcome on the basis of which treat-
ments are then compared within that subgroup is a sub-
sidiary outcome. The index outcome generally is the
primary outcome in the trial. At times, however, it is not.
Next, we give six examples of OBSGA from the medical lit-
erature to illustrate the variety of ways in which it occurs.
Example 1. Lung cancer chemotherapy
Sundstrøm et al. [19] randomized small-cell lung cancer
patients to etoposide and cisplatin (EC, n = 218) versus
cyclophosphamide, epirubicin, and vincristine (CEV, n =
218). The respective two- and five-year overall survival
rates for EC were 14% and 5%, and for CEV, they were 6%
and 2%, (log-rank test p < 0.01).
A quality of life (QOL) study based on several functional
and symptom scales applied at nine time points (the sub-
sidiary outcomes) was also done. Only 316 (72%) of the
patients consented for it. Further, due to death and other
reasons, the number of available cases dropped to 115 by
week 54. At week 54, the QOL study included 13% (n =
29) of CEV, and 19% of EC (n = 42) randomized cases.
Example 2. Cell transfusion in critical care
Does epoetin alfa reduce the need for red-cell transfusions
in critically ill patients? Corwin et al. [20] examined this
issue by randomizing 1460 cases in an intensive care facil-
ity to either epoetin alfa (n = 733) or placebo (n = 727).
At 29 days, 46% of the former, and 48% of the latter had
had a red-cell transfusion (Cochran-Mantel-Haenszel test
p = 0.34).
Here, the number of red-cell units transfused was a sub-
sidiary outcome with mean and median values only given
for the transfused cases. Treatment-wise comparison for
this outcome in this subgroup yielded a Wilcoxon-Mann-
Whitney test p = 0.69.
Example 3. Treatment strategies for stroke
Bernhardt et al. [21] is a phase II randomized trial of the
safety and feasibility of very early mobilization with
standard care (n = 38) as compared to only standard care
(n = 33) for stroke patients. By month 3, 21% (8) of the
former and 9% (3) of the latter had died (Fisher's exact
test p = 0.20).
The numbers of serious and nonserious adverse events
among the three month survivors were used as subsidiaryPage 2 of 10
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was 0.85 and for the latter it equaled p = 0.04.
Example 4. Probiotics and atopic dermatitis
Does Lactobacillus GG (LGG) prevent the development of
atopic dermatitis (AD) in newborns? Kopp et al. [22] ran-
domized 105 pregnant women from families with an
atopic disease to either LGG (n = 54) or placebo (n = 51)
to address this issue. Occurrence of AD by the age of two
was the primary (index) measure. Of the 50 LGG and 44
placebo children completing the trial, 28% and 27%,
respectively, were diagnosed with AD (chisquare test p =
0.93).
The severity of AD after two years was the subsidiary out-
come. Median values on the Scoring Atopic Dermatitis
Index (LGG = 18.5 & placebo = 22.5) were reported and
compared only for the children diagnosed with AD (Wil-
coxon test p = 0.80).
Example 5. Antibiotics for acute otitis media
McCormick et al. [23] randomized children with nonse-
vere acute otitis media to either watchful waiting (WW, n
= 111) or immediate antibiotics (IABX, n = 112). Carriage
of resistant bacterial strains at day 12, one of the four pri-
mary outcomes, occurred in 16% (18) of the IABX group
and 39% (43) of the WW group (our chisquare p < 0.01).
With culture growth status as the index outcome, two sub-
sidiary outcomes based on it were: (i) the count of antibi-
otics to which the bacterium was resistant, and (ii) the
level of resistance to penicillin. With the data for (i)
shown in Table 1, among the culture positive cases, the
WW group had a lower proportion of cases resistant to a
larger number of antibiotics (chisquare p < 0.02). An anal-
ysis of resistance to penicillin yielded a similar finding.
Example 6. An arrhythmia suppression trial
Cowley et al. [24] randomized 48 suspected acute myocar-
dial infarct patients to lorcainide, an antiarrhythmic drug,
and 47 to a matching placebo for six weeks. The index,
though not the primary, outcome was survival to week 6.
There were sixteen subsidiary outcomes derived from 24-
hour ECG records at three time points: first 24 hours, day
6, and during week 6. Occurrence of severe arrhythmias
(SA) was the main subsidiary outcome as well as the pri-
mary outcome of the trial. The main time point for this
was, however, not uniquely or clearly specified.
Due to death or loss from the study, 80 of the 95 patients
were available at the first time point; 78 at the second, and
58 at the third. By week 6, 19% (9) lorcainide and 2% (1)
placebo patients had died (No statistical significance is
ascribed; our p = 0.01).
In the 48 subsidiary comparisons, five were significant at
the 0.01 level. At week 6 in particular, 8% (2) of the avail-
able 24 lorcainide patients, and 38% (13) of the 34 avail-
able placebo patients had SA. (The former is erroneously
stated as 13%, and no p-value is given; our p = 0.01).
Looking at all their data, the authors conclude:
Lorcainide was shown to be an effective anti-arrhyth-
mic agent. The study was not designed to evaluate the
effect of lorcainide on survival, ...
Table 2 summarizes these six examples. In each case, the
analysis of a subsidiary outcome was done within a sub-
group determined by a specific level of the index outcome.
They constitute but a small facet of the wide variety of out-
come based subgroup analyses that continue to be
reported in the clinical trials literature.
Practical Concerns
A crucial distinction between baseline and outcome based
subgroups is that while the size and composition of the
former are determinable when randomization ends, those
of the latter are not until the end of the trial. The latter also
does not allow a separate subsidiary outcome analysis for
all the subgroups. A QOL comparison among the dead,
for example, cannot be done. These differences notwith-
standing, the typical outcome based subgroup analyses
seen in the literature tend to exhibit most of the problems
associated with baseline based SGA that we listed in the
introduction.
Reduced Power
OBSGA is done for a subset, at times quite a small subset,
of the trial sample. In Example 1, OBSGA at 54 weeks was
done for less than 20% of the cases; in Example 2, for less
than 50%, and in Examples 4 and 5, for less than 30%. In
Example 6, about 60% of the sample was available for the
evaluation at the final time point. The power to detect
clinically meaningful effects, especially when the study
has a moderate or small sample size to start with, is then
reduced considerably.
Table 1: Number of non-sensitive antibiotics
Number IABX WW
0 0 13
1–3 8 18
4–6 10 12
Negative Culture* 94 68
Source: Table Six. McCormick et. al. [23]
* Includes 5 cases with missing data.Page 3 of 10
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None of the Examples 1 to 5 clearly states if the OBSGA
was pre-planned or allowed for in the sample size calcula-
tion. In Example 6, the subsidiary outcome was the pri-
mary outcome, with the level of statistical significance
apparently at 0.01. But the outcome was measured in a
number of ways, a large volume of data collected at sev-
eral time points, and the rationale for not designating sur-
vival also as a primary outcome is subject to question. The
large number of subsidiary analyses done in such cases
raises the false positive error rate, and at times, does so
substantially. In Example 1, QOL was evaluated at nine
points in time, using 14 scales. A total of 119 significance
tests appear in Tables One-Five of the paper. A similar sce-
nario prevails in Examples 3 and 6. Such analyses resem-
ble fishing expeditions for statistical significance.
Selective Reporting
With multiple, unplanned, and data driven analyses, the
potential for selective highlighting of only the significant
findings is enhanced. Examples 3 and 6 appear to exhibit
this tendency. Without access to trial protocol and records
such practices cannot be verified.
Over Interpretation
Reduced power, biased comparison (see below), and a
high false positive rate render the conclusions of an
OBSGA as tentative, at best. Yet, authors do not interpret
them with caution. In all these six examples, such findings
attain a greater credence than they deserve.
Biased Analysis
The key issue for SGA is the presence, size and direction of
an interactive effect between treatment and a risk factor.
That effect may occur in a masked fashion, and is not easy
to detect unless the sample size is quite large. For baseline
determined subgroups, we may analyze the trial data for
interaction even when close baseline balance prevails. But
this needs to be done with a preplanned appropriate test
that includes all the randomized subjects. Otherwise, the
exercise can do more harm than good.
For outcome based subgroups, the situation is more com-
plex. In the first place, the baseline factors exercising main
and interactive effects on treatment may be different for
the index and subsidiary outcomes. Furthermore, these
two outcomes may also impact each other. For example,
poor QOL may, independent of other factors, lower the
chance of survival. In such a situation, despite randomiza-
tion, patients on distinct treatment arms within an out-
come based subgroup are not likely, even on average, to
be similar in terms of baseline features. Furthermore,
biases introduced during the course of the trial like differ-
ential care, follow up and evaluation can influence the
composition of treatment subsets within the subgroup as
well.
To illustrate how such interactive effects are manifested,
we present, in Table 3, data from six hypothetical trials
(labeled Trial A to Trial F) of an antiarrhythmia drug. The
arrhythmia suppression trial of Example 6 forms the back-
drop for these data. Each trial randomized 200 patients to
either an antiarrhythmic drug (n = 100) or placebo (n =
100). Two outcomes were recorded six weeks later: sur-
vival and the level of arrhythmia (SA or Not SA).
We start with Trials A, B & C. In each of them, 50 drug and
25 placebo cases had died by week 6 (p < 0.01). Further,
10 of the 50 drug survivors, and 35 of the 75 placebo sur-
vivors had SA (p < 0.01). In line with Cowley et al. [24],
we may then infer that the drug, though without a survival
benefit, is an effective antiarrhythmic.
Now suppose the baseline arrhythmia levels in Trials A, B
& C were as shown in Table 3. In each, there is exact base-
line balance in terms of this factor, with the baseline odds
ratio for SA (BOR(SA)) between treatment and control
groups equal to 1.00. Despite this and identical overall
outcomes, the outcome patterns within the subgroups
defined by baseline severity of arrhythmias were quite dif-
ferent in the three trials.
In Trial A, for those without initial SA, the drug and pla-
cebo had identical effects on survival and progression to
SA at week 6. For those with initial SA, however, the drug
reduced the week 6 survival rate from 50% to 0%. The
excess of SA in the placebo group at week 6 does not
reflect a beneficial effect of the drug but simply the
Table 2: Varieties of index and subsidiary outcomes
Example Disease Index Outcome Subsidiary Outcome
1. Sundstrøm et al. [19] lung cancer survival quality of life
2. Corwin et al. [20] critical illness red-cell transfusion number of units transfused
3. Bernhardt et al. [21] stroke survival adverse events
4. Kopp et al. [22] AD* occurrence of AD severity of AD
5. McCormick et al. [23] AOM† isolation of bacteria level of antibiotic resistance
6. Cowley et al. [24] AMI‡ survival severity of arrhythmia
* AD: atopic dermatitis; † AOM: acute otitis media; ‡ AMI: acute myocardial infarctionPage 4 of 10
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the survivors, the BOR(SA) is 0.00, indicating a potential
selective interactive effect at work.
In Trial B, on the other hand, the drug seems to be harm-
ful only for those who did not have SA at the start. While
50% of placebo cases without SA at the outset tend at the
worst to develop SA by week 6, 50% of similar cases on
the drug die by week 6. Possibly for those who first
develop SA while on the drug, the arrhythmias tend to be
of sufficient severity as to cause death. The drug thus
harms patients without SA, but otherwise is not different
from placebo. The BOR(SA) for the survivors is 2.00, indi-
cating the possible presence of a different type of selective
interactive effect.
In Trial C, the drug appears to affect a higher death rate
than placebo whether or not the subject had SA at the
start. Similarly, among the survivors, those on the drug
had a lower proportion of SA compared to placebo irre-
spective of baseline status, though the magnitudes of
these difference are not the same. And, among the survi-
vors in this trial, the changed BOR(SA) of 0.50 may
denote an interactive effect.
Now consider Trials D, E & F. The overall results for these
three trials are also identical. In each, the death rate at
week six on the drug was 20% while that on placebo was
40% (p < 0.01); among the survivors, 60 out of the 80
(75%) in the drug arm had SA at week 6 while 40 out of
60 (66%) in the placebo arm had this condition (p =
0.28). The usual analysis thereby indicates that the drug
improves survival but does not noticeably improve
arrhythmia severity among the survivors. However, in
each trial, a moderate but statistically significant baseline
difference prevailed: 50% of the drug arm had SA at base-
line but only 36% of the placebo cases were so affected (p
< 0.05). The complete sample BOR(SA) for each trial was
1.80. Hence, the directions of the observed differences as
well as the higher proportion of the more severely afflicted
cases in the drug group needs to be kept in mind when
drawing our conclusions.
Trials D, E & F also exhibit distinct interactive scenarios
(Table 3). In trial D, the death rate among those without
baseline SA is higher for the drug group than for placebo
(20% versus 6%) but the situation is reversed for those
with SA at baseline (20% versus 100%). But in terms of SA
among the survivors, the difference between the two
groups is a marginal one for those without baseline SA
and indeterminate for those with baseline SA. The pattern
for the two outcomes viewed in a combined way for the
drug also does not seem to depend on baseline status.
Among the survivors, the BOR(SA) has risen to 8 (note, it
was 1.80 for all the randomized cases).
In Trial E, the results for survival are the opposite of those
for Trial D. Here the death rate among those without base-
line SA is lower for the drug group than for placebo (20%
versus 62%). The antiarrhythmic effect of the drug is
much more pronounced among those with baseline SA
compared to those without baseline SA. The BOR(SA) for
the survivors of Trial E is 0.67.
Trial F, on the other hand, differs from Trials D & E, in that
the drug has a lower death rate compared to placebo for
those with baseline SA and those without it. But the
antiarrhythmic benefits of the drug seem more pro-
Table 3: Baseline status and week 6 outcome
Baseline: No SA Baseline: SA Baseline: No SA Baseline: SA
Week 6 Status Drug Placebo Drug Placebo Drug Placebo Drug Placebo
Trial A Trial D
Alive & No SA 40 40 0 0 10 20 10 0
Alive & SA 10 10 0 25 30 40 30 0
Dead 0 0 50 25 10 4 10 36
Trial B Trial E
Alive & No SA 25 25 15 15 0 20 20 0
Alive & SA 0 25 10 10 40 4 20 36
Dead 25 0 25 25 10 40 10 0
Trial C Trial F
Alive & No SA 35 30 5 10 10 20 10 0
Alive & SA 5 20 5 15 40 34 20 6
Dead 10 0 40 25 0 10 20 30
Note: Trials A, B, C ⇒ exact baseline balance; Trials D, E, F ⇒ moderate baseline imbalancePage 5 of 10
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Trial F, at 5.4, is also higher than the 1.80 value for the
overall sample.
The key message from these hypothetical trials is that the
issue of interaction in outcome based subgroups is a more
complex affair than for baseline subgroups. Whether base-
line balance prevails or not, similar overall data for the
index and subsidiary outcomes may arise from quite dis-
tinct and even conflicting underlying scenarios.
The approach in the overall analyses of the subsidiary out-
come in these trials is the same as in all the real data exam-
ples we gave. In a QOL study, Trials A, B & C would thus
imply that the drug may reduce survival but at least
improves the QOL among the survivors. Our hypothetical
examples show such an interpretation of subsidiary out-
come data, in particular, needs to consider the possibility
of a complex web of relationships linking baseline factors
and treatment on the one hand to the index and subsidi-
ary outcomes on the other, and those linking the two out-
comes to each other as well. In part, this is indicated by
the fact that in each of the six trials, the distribution of the
baseline risk factor in treatment subsets in the outcome
based subgroup is different, and often very different, from
the pattern at randomization. Unlike baseline subgroups,
this is not just a matter of chance but a possible systematic
consequence of such interactive effects. The typical analy-
sis of the subsidiary outcome thereby also carries a strong
inherent potential for bias.
To conclude this section: The impact of key prognostic fac-
tors, and their linkages to the index and subsidiary out-
comes are often unknown. Randomization does not
mitigate outcome based imbalances. With a marked pos-
sibility of bias, the typical OBSGA seen in practice is unre-
liable. Whatever the extent of initial confounding, a
separate second outcome analysis for a subset of subjects
determined by the value of an index outcome is necessar-
ily suspect [13].
Alternative Analyses
Subsidiary outcomes like severity of arrhythmias, QOL
and the others noted in our examples often are important
clinical outcomes. Appropriate approaches for the analy-
sis of such outcomes are hence needed.
It is now recommended that the analysis of baseline based
SGA, when warranted by design, should be done with an
appropriate test for interaction. That, however, does not
resolve all the issues. First, these tests have low power. Sec-
ond, the distinction between biologic and statistical inter-
action, and the choice of a metric to measure interaction
are important matters that need further resolution.
The root of the concern with outcome based subgroup
analysis is also a possible presence of complex interactive
effects. However, its resolution does not seem to lie in a
search for a test for interaction. First, the relevant baseline
factors and the manner in which they impact the two out-
comes are not often known. Second, the key question for
outcome based analysis of the overall data is not so much
how to directly assess the presence of such interactive
effects but rather how to adjust, in an unbiased way, for
the impact and results of the index outcome when analyz-
ing the subsidiary outcome. That is, when considering the
severity of arrhythmias or QOL among the survivors,
should we adjust for the difference, if any, between the
treatment groups in terms of death rates? If so, how
should we do it?
At first sight, we may regard this as a missing data prob-
lem, and apply one of the several available imputation
methods to deal with it [25]. The two texts on the analysis
of QOL data, in particular, raise the issue of missingness
through attrition, non-response or death [26,27]. But,
they do not go on to describe how to address outcome
(death) based missingness. Also note that even when
missingness is due to drop out, loss to follow up, or simi-
lar reasons, most published QOL analyses employ com-
plete case analysis, and not imputation, to deal with the
problem [28].
The new step would thus be to impute the values of the
subsidiary outcome for cases in whom the index outcome
generally precludes their existence. A major advantage
would be the inclusion of all randomized subjects in the
analysis and removal of baseline factors related bias.
There are, however, two disadvantages here. One, the
usual missing data methods are predicated on assump-
tions like missing at random that cannot be justified in
the present context. According to Yusuf et al. [13], and as
illustrated earlier, they are unlikely to hold. Two, for
OBSGA, we have values that are not only unknown but
also unknowable. To impute a low or moderate quality of
life or arrhythmia level to a dead person does not appear
appropriate. If you are dead, you are dead.
Another approach for OBSGA is to explicitly adjust out-
come based comparisons in terms of potential confound-
ing factors. In theory, this approach has less potential for
bias than simply assuming that the unknowable values
are missing at random. In practice, though, several hur-
dles remain. One, those factors are rarely known in
advance. Attempts to identify them post hoc will enhance
the false positive rate and turn the exercise into a fishing
expedition. Two, outcome related subgroups are often
small, and their sizes cannot be planned in advance.
Three, for the purpose of adjustment, we need a statistical
model that not only incorporates the interactive impact ofPage 6 of 10
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comes but also the relation between the two outcomes.
Some conditional probability models that explicitly
adjust for post-randomization variables have been devel-
oped, and may be adapted to this task [29]. However, this
option requires more work to produce realistic and inter-
pretable models, develop analytic strategies, and test them
with real and simulated data.
Analyzing outcome based data thereby poses a distinctive
challenge in terms of methods and interpretation. Com-
paring within outcome based subgroups can be unreliable
even when baseline confounding appears absent. Under
these circumstances, we suggest two simple strategies to
avoid bias. Both of them take off from the observation
that by excluding some of the randomized cases, OBSGA
violates the intent-to-treat principle. To remedy this, we
perform the subsidiary outcome analysis for the treatment
groups as randomized. But unlike the classic missing data
approach whereby subsidiary outcome values for the cases
for whom they cannot be measured are ascribed by posit-
ing missingness at random or a similar mechanism, we
ascribe these values on clinically or practically appropriate
grounds.
Let us denote the usual separate analysis of an outcome
based subgroup as Analysis I. Then, the two alternatives
we suggest are as follows:
Analysis II: Ascribe the worst or best possible outcome, as
clinically appropriate, for the subsidiary outcome to the
subjects excluded by Analysis I. In a QOL assessment, for
example, the dead cases are ascribed the lowest possible
QOL score.
Analysis III: Ascribe a lower or higher level of outcome
than the worst or best possible level, as clinically appro-
priate, of the subsidiary outcome to the subjects excluded
by Analysis I. In a QOL assessment, the dead subjects get
a QOL score lower than the lowest possible QOL score.
Analyses II and III thus resemble the best or worst out-
come imputation used in the intent-to-treat analysis con-
text. Their advantages are the inclusion of all subjects as
randomized, control of the bias of Analysis I, and possibly
higher power due to the larger sample size. Further, the
findings of these analyses should be taken in conjunction
with the analytic results for the index outcome.
Before turning to the specifics, we note a distinction.
These approaches may be seen as constructing a compos-
ite outcome [30]. In a sense, this is true; for we do use the
survival (index) outcome to extend the construction of the
QOL (subsidiary) outcome. The crucial difference is that
we do not seek a single outcome for the trial. We analyze
these outcomes separately. The index outcome is, how-
ever, incorporated into the analysis of the subsidiary out-
come.
The first practical question is how to choose between
Analysis II and Analysis III. At times, the types of out-
comes in the trial make that choice clear. Suppose the
index outcome is the occurrence of an event, and the sub-
sidiary outcome is the number of (the same) events
among those for whom the event occurred. In that case,
we prefer Analysis II with a zero value for those excluded
by Analysis I. But at other times, the choice is not clear cut,
and can affect the interpretation. In our view, that choice
needs to made in consultation with subject matter experts.
The second question pertains to the specific analytic tech-
nique to use. That, we hold, should reflect the nature of
the data. Thus, for an ordered subsidiary outcome, a trend
type of analysis is often better. The third question is the
assignment of the lowest score for Analysis III. That matter
also needs consultation with subject matter experts. And,
furthermore, all these choices need to be made a priori and
written into the data analysis protocol.
Now, we consider our examples. We set aside Examples 1
& 3 due to complexity of the analysis given in the respec-
tive papers and non-availability of the requisite data to
perform our analyses. Examples 2 & 5 fall in the category
where Analysis II is clearly the analysis of choice. These are
reanalyzed first.
Example 2: The comparison of the number of red-cell
units transfused done in the paper excluded subjects who
were not transfused. Analysis II includes them with this
number put at zero. This yields p = 0.45 with the t-test, a
result similar to the one reported. In part, this is due to the
fact that the treatment groups had similar index out-
comes; had that not been the case, the two analyses could
have differed markedly.
Example 5: Analysis II puts the count of resistant antibiot-
ics for culture negative cases at zero. Analysis I uses the
first three rows of Table 1, giving p < 0.01 for trend. Anal-
ysis II adds the last row to the first, producing a trend p =
0.14. Analysis II hence gives a more guarded conclusion
compared to Analysis I, while avoiding its bias.
When the index and subsidiary outcomes differ in sub-
stance, like survival and QOL (Example 1), or survival and
arrhythmia level (Example 6), choosing between Analysis
II and Analysis III poses a particular challenge.
Example 4: Analysis II includes those who did not con-
tract AD by putting their AD severity level at the lowest
value, and Analysis III would chose a lower score. As the
relevant data are not given, we cannot do this analysis.Page 7 of 10
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vival rate. Analysis I declares the rate of SA significantly
smaller for the drug than for placebo (p = 0.01). For Anal-
yses II and III under the worst-case intent-to-treat
approach, the lost to follow up cases were combined with
the dead cases in each group. Analysis II then contradicts
Analysis I (p = 0.91), and so does Analysis III (p = 0.26).
Analysis II possibly has a relatively unclear clinical mes-
sage. The short follow up time may have clouded the
results as patients with SA remained at higher risk for
death. Analysis III, with the index (dead) cases a separate
category, appears better.
Trials A, B & C: Analysis II combines the dead with alive &
SA. In both groups, 60 out of 100 were dead or had SA,
and 40 were alive without SA (p = 1.00). Analysis III based
on a three level ordered outcome shows a marginally sig-
nificant trend (p = 0.05). The drug induces higher fatality
at six weeks, but among the survivors, a smaller propor-
tion on it have SA. This is not too different from Analysis
I, but the bias is avoided.
Trials D, E & F: The drug confers a significant survival ben-
efit at week 6 (p < 0.01). For the rate of SA, Analysis I
shows that the drug group is not that different from pla-
cebo (p = 0.28). Analysis II reiterates this message (p =
1.00), but Analysis III finds a significant trend (p = 0.04).
While avoiding the bias of Analysis I, Analyses II and III
may produce a similar or a different message. Which one
is more reliable? None, in our view, necessarily has higher
power than the other. The nature of the specific subsidiary
outcome and the statistical techniques used as well influ-
ence the answer. In Trial A, for example, pooling the dead
with those who were alive but with SA gave a coarser out-
come variable, and seems to have reduced power. But with
different trial results that may not be so. Also, if, on the
other hand, the subsidiary outcome was measured on a
five ordered categories scale, Analysis II may be advisable.
More studies are needed before we can lay out the condi-
tions where Analysis II is preferrable over Analysis III, or
vice versa.
The resolution of such questions requires simulation stud-
ies utilizing appropriate statistical models that incorpo-
rate the complex web of interactive effects possibly at
work. Further, such studies need to compare these analy-
ses with one based on a relevant multivariate conditional
probability model for such data. Avenues for sensitivity
analysis like the best or worst case scenarios to check the
robustness of the alternatives we propose, and guidelines
for assigning the subsidiary outcome scores also need to
be developed.
Ultimately, the basic issues at hand are not just statistical
issues but ones that also depend on patient values and
preferences, and need input from clinicians in the field. Is
death worse than a very poor quality of life, or very severe
disease? Or is it more or less the same? How much relative
weight does one put on death compared to life with
extreme pain and suffering?
These are not easy questions. Yet, all analyses of outcome
based data, implicitly or explicitly, posit and provide
some form of an answer to them. Analysis I does so
implictly and in a biased manner. Analyses II and III posit
the issue more explicitly and provide an unbiased way to
deal with it. However, more research and ethical consulta-
tions are required to produce field specific satisfactory
answers to them.
Conclusion
Analysis of a second outcome for cases at one level of an
initial outcome is a form of improper subgroup analysis.
In practice, it manifests most of the problems that have
been noted with baseline based subgroup analysis. Also,
as the subgroups are outcome determined, there is an
intrinsic potential for bias associated with it. We have
illustrated that conclusions based on it can be unreliable
whether or not baseline confounding exists, and a partic-
ular conclusion may simultaneously reflect quite distinct
underlying scenarios.
The guidelines in Wang et al. [12] for the usual SGA
thereby need to be applied to outcome based subgroup
analysis as well. When warranted, OBSGA has to be
planned in advance, allowed for in sample size computa-
tion, use an adjusted a-level, and follow an appropriate
method that accords with the intent-to-treat principle.
Furthermore, due caution should always be exercised in
interpreting its findings.
Our preliminary survey shows that OBSGA is frequently
undertaken in the medical literature. Yet, it is not recog-
nized as such. The strong warning issued against it by
Yusuf et al. [13] has been ignored. In this paper, we once
again draw attention to the practice and show some of the
varied forms it assumes in clinical trial papers. Surveys
done across different medical fields are, however, needed
to document the extent and nature of the practice.
We have provided two simple alternatives that avoid bias,
maintain the integrity of randomization and follow the
intent-to-treat principle. Instead of excluding cases based
on the index outcome, we incorporate them in the analy-
sis of the subsidiary outcome in a clinically meaningful
and statistically appropriate manner. In a cancer trial with
survival and QOL as the outcomes, this implies that while
the survival analysis is done in the usual manner, for com-Page 8 of 10
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or a lower QOL score.
These, however, are preliminary recommendations.
Detailed studies with real and simulated data to assess
their accuracy and precision in a variety of circumstances
are needed. We hope our work will promote the needed
research on the issue of outcome based subgroup analysis.
In conclusion: A cartoon shows a dentist boasting that his
patients have 50% fewer cavities. His colleague then
retorts, "That's because they have 50% fewer teeth"
(Moore [31], page 161). Talking of the former without the
latter can mislead; that is the key flaw of outcome based
subgroup analysis. In principle, statisticians are well
aware of this problem. Yet, a form of analysis with such a
flaw has, despite the warning given by experts in a leading
journal, entrenched itself in the clinical trial literature. It
is time a further critical look at it was undertaken.
Methods
This paper is not a comprehensive survey of OBSGA. Nor
is it a technical work on statistical methodology. Rather, it
has been written to highlight, illustrate, explain, reflect on
and provide reasonable preliminary solutions for a crucial
but neglected issue.
Our examples of OBSGA are derived from an ad hoc
search of medical journals. From the cases found, we
selected six that well illustrate the diverse manner in
which it occurs. They are not presented as representative
cases of OBSGA. We also use these examples to illuminate
the similarities and differences between outcome and
baseline based subgroup analyses. For each example, we
noted the index and subsidiary outcomes, and summa-
rized the analysis of the subsidiary outcome given in the
source paper. Taking the one example where detailed data
were available, we constructed six artificial data sets to
argue how the typical way in which subsidiary outcomes
are analyzed is not only biased but also may be invalid
and perhaps derive from contrasting underlying situa-
tions. Some of the hypothetical scenarios are extreme, but
they have been chosen to make the point clearly; other
scenarios consistent with the overall results can be con-
structed as well.
Unless noted otherwise, the p-values in the Biased Analy-
sis and the Alternative Analyses subsections are computed
from the regular chisquare test. For trend analysis, the
Cochran-Armitage trend test was used. All p-values com-
puted or cited from the literature have been rounded to
two decimal digits. For ease of exposition, we do not give
confidence intervals.
For the hypothetical trials, the extent of baseline imbal-
ance in terms of a risk factor was measured by the ratio of
the odds of the high level of this factor between treatment
and control groups at baseline. The disparity in this ratio
between the survivors and the whole sample is used as an
indicator of underlying interactive effects. The difference
in the odds ratio is not necessarily the best measure of an
interactive effect, and we also need to distinguish between
biologic and statistical interaction. In the absence of a
model linking the index and subsidiary outcomes to base-
line factors and each other, our odds ratio comparisons
are mainly meant to raise awareness of interactive effects,
and not to provide a firm measure for them.
In the analysis we present, we employ a binary subsidiary
outcome. However, our arguments readily extend to mul-
tilevel and continuous subsidiary outcomes.
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